Novel treatment for orphan disease. Promising in-vivo data.

About

An adeno-associated virus-based recombinant gene therapy vector for the treatment of a retinal disorder, specifically Leber's congenital amaurosis and retinitis pigmentosa, due to mutations in Crumbs homologue-1. LCA and RP are rare genetic disorders, caused by mutation in the Crumbs homologue-1 (CRB-1) gene, with prevalences of 1/40,000 and 1/3,000 respectively. Scientists from Leiden University Medical Center (LUMC) and the Netherlands Institute for Neuroscience of the Royal Netherlands Academy of Arts and Sciences (KNAW) have developed an adeno-associated virus (AAV)-based recombinant gene therapy vector for the treatment of a retinal disorder, specifically Leber's congenital amaurosis (LCA) and retinitis pigmentosa (RP), due to mutations in Crumbs homologue-1 (CRB-1). Presently there are no therapeutics or effective treatments available to prevent, delay or treat LCA or RP in humans. Therefore, there is a need for methods and means for the treatment of retinal disorders due to mutations in CRB1. LUMC has attracted significant funding for the preclinical development and Phase I/IIa clinical trial. We are currently looking for a development partner to collaborate, contribute expertise and / or provide matching funds for the clinical development stage, in return for a license or exclusive option to license the know-how and global patent family. This project is a unique opportunity for a public-private partnership to develop a treatment for a rare orphan disease.  Key Benefits Novel treatment for orphan disease Promising in-vivo data Applications Retinal disorders: Leber's congenital amaurosis Retinitis pigmentosa Development Stage Positive in-vivo testing Start of GMP validation Patent Status Patent in national phase EP, US, CN, JP, CA, AU, IL, IN   

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations